吉利德（Gilead）排名第一Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
FOSTER CITY, Calif., May 25, 2022 /3BL Media/ Gilead Sciences, Inc. (Nasdaq: GILD) was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, found at:https://www.fcaaids.org/inform/philanthropic-support-to-address-hiv-aids/, is released annually and is widely regarded as the most comprehensive study of its kind. It analyzes 2020 funding data (the most recent year available) revealing that Gilead’s philanthropic support wholly drove the increase of private HIV and AIDS philanthropic funding – representing 38% of all HIV funding and driving a majority of the increases in funding across all issues, populations and geographies. Gilead is also recognized in the report as the number one funder in the U.S. and the number three funder internationally. The report indicates that, “Private HIV and AIDS philanthropic funding to the U.S. rose for the seventh year in a row, totaling over $321 million in 2020, a dramatic 52% ($109 million) increase from 2019.”
除了被认为是整体和在美国的第一大资助者外，吉利德还被认为是一系列类别中的第一大筹款人，包括：
- Number one funder addressing the COVID-19 pandemic
- Number one funder of Black, Indigenous and people of color communities in the U.S.
- Number one corporate funder
“Gilead's support for community organizations is part of our enduring commitment to ending the HIV epidemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “We believe that real progress is only possible through collaboration and partnership. That is why we invest in the extraordinary efforts our partners are undertaking to reach underserved populations, eliminate barriers to care and educate communities. It is inspiring to see the work that goes on across these groups and we are proud to play a role in supporting them.”
吉利德（Gilead）的慈善努力是通过许多签名计划和计划来管理的，旨在覆盖美国和世界各地的关键人口和社区。
RADIAN®，于2019年由埃尔顿·约翰·艾滋病基金会（Elton John Aids Foundation）推出，解决了东欧和中亚的挑战，在该挑战中，年度艾滋病毒诊断率持续上升。在美国。，HIV Age阳性®aims to improve the health and quality of life for those who are aging andTRANScend®supports Trans-led organizations improving the safety, health and wellness of the Transgender community.
为了协助受赠者，他们因199年大流行而面临即将关闭或终止服务的授予者，188bet上不了吉利德在乎was launched in 2020, providing up to $20 million in donations to nonprofit groups. The GileadCOMPASS Initiative®这是与社区组织的十年，100万美元的合作伙伴关系，正在努力打击美国南部的艾滋病毒流行病，188bet网址怎么打不开并负责推动整个美国南部的资金急剧增加，而美国南部的资金一直在下降。前两年。
According to the report, “In 2020, funding disbursements to the U.S. South increased sharply, by $28 million (76%), after having declined the two previous years. Again, as in 2017, this increase is largely attributed to large disbursements for Gilead’s COMPASS Initiative. COMPASS funding is distributed to its coordinating centers, located across the U.S. South, in large sums, but is then granted out into the community over a couple of years.”
有关Gilead的签名资金计划和计划的更多信息，请参见：https://www.gilead.com/purpose/partnerships-and-community
关于吉利德科学
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Today, millions of people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
For more information about Gilead, please visit the company’s website atwww.gilead.com，在Twitter（@Gilead Sciences）上关注Gilead，或致电1-800-Gilead-5或1-650-574-3000致电Gilead公共事务。
Jacquie Ross, Investors
（408）656-8793
Hayley Home, Media
(916) 402-286
